Cargando…
Daily Management of Patients on Multikinase Inhibitors’ Treatment
In a minority of differentiated thyroid cancer (TC) cases and in a large percentage of poorly differentiated TCs (PDTCs) and anaplastic TCs (ATCs), the prognosis is poor due to the lack of response to conventional treatments. In the last two decades, multikinase inhibitor (MKI) compounds have been d...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290676/ https://www.ncbi.nlm.nih.gov/pubmed/35860593 http://dx.doi.org/10.3389/fonc.2022.903532 |
_version_ | 1784748959061770240 |
---|---|
author | Colombo, Carla De Leo, Simone Trevisan, Matteo Giancola, Noemi Scaltrito, Anna Fugazzola, Laura |
author_facet | Colombo, Carla De Leo, Simone Trevisan, Matteo Giancola, Noemi Scaltrito, Anna Fugazzola, Laura |
author_sort | Colombo, Carla |
collection | PubMed |
description | In a minority of differentiated thyroid cancer (TC) cases and in a large percentage of poorly differentiated TCs (PDTCs) and anaplastic TCs (ATCs), the prognosis is poor due to the lack of response to conventional treatments. In the last two decades, multikinase inhibitor (MKI) compounds have been developed and demonstrated to be very effective in these aggressive cases. Besides the great efficacy, several adverse events (AEs) have been reported in virtually all patients treated with MKIs, largely overlapping between different compounds and including hypertension, diarrhea, anorexia, decreased weight, fatigue, and proteinuria. Most grade 3–4 adverse reactions occur during the first 6 months of treatment and require dosage reduction and/or drug discontinuation. Due to severity of the AEs related to the treatment with MKIs, a multidisciplinary team is definitely required for the daily management of these patients, for the evaluation of the disease status, and the psychophysical condition. Moreover, it is crucial that the patients could have a facilitated access to reach either specialist doctors or nurses who must have been trained to follow them for their individual clinical complications. The follow-up visits should take place at monthly intervals until the sixth month and then every 1–2 months until the completion of the first year of treatment. The flow chart followed at our tertiary center is reported in the present review as a real-life-based example for the follow-up of patients with advanced TC on MKI treatment. |
format | Online Article Text |
id | pubmed-9290676 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92906762022-07-19 Daily Management of Patients on Multikinase Inhibitors’ Treatment Colombo, Carla De Leo, Simone Trevisan, Matteo Giancola, Noemi Scaltrito, Anna Fugazzola, Laura Front Oncol Oncology In a minority of differentiated thyroid cancer (TC) cases and in a large percentage of poorly differentiated TCs (PDTCs) and anaplastic TCs (ATCs), the prognosis is poor due to the lack of response to conventional treatments. In the last two decades, multikinase inhibitor (MKI) compounds have been developed and demonstrated to be very effective in these aggressive cases. Besides the great efficacy, several adverse events (AEs) have been reported in virtually all patients treated with MKIs, largely overlapping between different compounds and including hypertension, diarrhea, anorexia, decreased weight, fatigue, and proteinuria. Most grade 3–4 adverse reactions occur during the first 6 months of treatment and require dosage reduction and/or drug discontinuation. Due to severity of the AEs related to the treatment with MKIs, a multidisciplinary team is definitely required for the daily management of these patients, for the evaluation of the disease status, and the psychophysical condition. Moreover, it is crucial that the patients could have a facilitated access to reach either specialist doctors or nurses who must have been trained to follow them for their individual clinical complications. The follow-up visits should take place at monthly intervals until the sixth month and then every 1–2 months until the completion of the first year of treatment. The flow chart followed at our tertiary center is reported in the present review as a real-life-based example for the follow-up of patients with advanced TC on MKI treatment. Frontiers Media S.A. 2022-07-04 /pmc/articles/PMC9290676/ /pubmed/35860593 http://dx.doi.org/10.3389/fonc.2022.903532 Text en Copyright © 2022 Colombo, De Leo, Trevisan, Giancola, Scaltrito and Fugazzola https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Colombo, Carla De Leo, Simone Trevisan, Matteo Giancola, Noemi Scaltrito, Anna Fugazzola, Laura Daily Management of Patients on Multikinase Inhibitors’ Treatment |
title | Daily Management of Patients on Multikinase Inhibitors’ Treatment |
title_full | Daily Management of Patients on Multikinase Inhibitors’ Treatment |
title_fullStr | Daily Management of Patients on Multikinase Inhibitors’ Treatment |
title_full_unstemmed | Daily Management of Patients on Multikinase Inhibitors’ Treatment |
title_short | Daily Management of Patients on Multikinase Inhibitors’ Treatment |
title_sort | daily management of patients on multikinase inhibitors’ treatment |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290676/ https://www.ncbi.nlm.nih.gov/pubmed/35860593 http://dx.doi.org/10.3389/fonc.2022.903532 |
work_keys_str_mv | AT colombocarla dailymanagementofpatientsonmultikinaseinhibitorstreatment AT deleosimone dailymanagementofpatientsonmultikinaseinhibitorstreatment AT trevisanmatteo dailymanagementofpatientsonmultikinaseinhibitorstreatment AT giancolanoemi dailymanagementofpatientsonmultikinaseinhibitorstreatment AT scaltritoanna dailymanagementofpatientsonmultikinaseinhibitorstreatment AT fugazzolalaura dailymanagementofpatientsonmultikinaseinhibitorstreatment |